The findings from this study highlight the potential efficacy of CRISPR gene editing in the treatment of SCD and β-Thalassemia, as well as underscore the importance of expanding on HBG1/2 gene editing in the future. The gene discussed is HBG1; the disease is Schnyder corneal dystrophy.